These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 21205131)

  • 1. How to use virological tools for the optimal management of chronic hepatitis C.
    de Leuw P; Sarrazin C; Zeuzem S
    Liver Int; 2011 Jan; 31 Suppl 1():3-12. PubMed ID: 21205131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to use virological tools for optimal management of chronic hepatitis C.
    Chevaliez S; Pawlotsky JM
    Liver Int; 2009 Jan; 29 Suppl 1():9-14. PubMed ID: 19207960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chronic hepatitis C].
    Grammatikos G; Sarrazin C
    Dtsch Med Wochenschr; 2010 Dec; 135(50):2525-34; quiz 2535-8. PubMed ID: 21140330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
    De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
    Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virological tools to diagnose and monitor hepatitis C virus infection.
    Chevaliez S
    Clin Microbiol Infect; 2011 Feb; 17(2):116-21. PubMed ID: 21054664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of molecular parameters for routine assessment of viremia in patients with chronic hepatitis C who are undergoing antiviral therapy.
    Kessler HH; Pierer K; Santner BI; Vellimedu SK; Stelzl E; Marth E; Fickert P; Stauber RE
    J Hum Virol; 1998; 1(5):314-9. PubMed ID: 10195258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serine protease inhibitors as anti-hepatitis C virus agents.
    Reiser M; Timm J
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):537-47. PubMed ID: 19485794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of naive patients with chronic hepatitis C].
    Vince A; Duvnjak M
    Acta Med Croatica; 2009 Dec; 63(5):409-15. PubMed ID: 20198900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging therapies for hepatitis C virus.
    Birerdinc A; Younossi ZM
    Expert Opin Emerg Drugs; 2010 Dec; 15(4):535-44. PubMed ID: 20629602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Soriano V; Núñez M; Sánchez-Conde M; Barreiro P; García-Samaniego J; Martín-Carbonero L; Romero M; González-Lahoz J
    Antivir Ther; 2005; 10(1):167-70. PubMed ID: 15751774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of HCV RNA measurement for tailoring treatment duration.
    Peiffer KH; Sarrazin C
    Dig Liver Dis; 2013 Sep; 45 Suppl 5():S323-31. PubMed ID: 24091111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antiviral treatment of chronic hepatitis C].
    Berger A
    Med Monatsschr Pharm; 2012 Feb; 35(2):55-60. PubMed ID: 22400430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostics in hepatitis C: The end of response-guided therapy?
    Maasoumy B; Vermehren J
    J Hepatol; 2016 Oct; 65(1 Suppl):S67-S81. PubMed ID: 27641989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs in development for chronic hepatitis C: a promising future.
    Pockros PJ
    Expert Opin Biol Ther; 2011 Dec; 11(12):1611-22. PubMed ID: 21995412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virological tools for optimal management of chronic hepatitis C.
    Deltenre P
    Acta Gastroenterol Belg; 2009; 72(4):421-4. PubMed ID: 20163036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.